Who Can Participate?
Age Range
3-25
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
CONNECT 1906: Phase 2 trial of a novel peptide vaccine (PEP-CMV) targeting CMV antigen for newly diagnosed pediatric high-grade glioma (HGG) and diffuse intrinsic pontine glioma (DIPG) and recurrent medulloblastoma (MB).
Principal Investigator
Daniel
Landi
Protocol Number
PRO00109336
NCT ID
NCT05096481
Phase
II
Enrollment Status
Open to Enrollment